Today, the Office of National Drug Control Policy convened its first meeting of President Trump’s “Commission on Combating Drug Addiction and the Opioid Crisis.”
The Commission is tasked with making recommendations for improving the Federal response to opioid misuse and abuse.
Best evidence informs us that medical marijuana access is associated with reduced levels of opioid-related abuse, hospitalization, and mortality. Nonetheless, this administration continues to express skepticism with regard to the safety and efficacy of medical marijuana.
Today in The Hill newspaper, NORML Deputy Director Paul Armentano writes:
With opioid overdose deaths having risen four-fold since 1999, it is imperative that lawmakers and public health experts approach this issue with an open mind and remain willing to entertain all potential alternatives.
For many patients, cannabis provides a safe and effective substitute for the use of opioids and other potentially harmful substances. Committee members should set their political ideologies aside and give strong consideration to this rapidly growing body of scientific evidence.